<--- Back to Details
First PageDocument Content
Chemistry / Gilead Sciences / Medicine / Clinical medicine / Cyclopropanes / Breakthrough therapy / Combination drugs / Organofluorides / Sofosbuvir / Ledipasvir / Simeprevir / Velpatasvir/sofosbuvir
Date: 2016-06-28 12:26:37
Chemistry
Gilead Sciences
Medicine
Clinical medicine
Cyclopropanes
Breakthrough therapy
Combination drugs
Organofluorides
Sofosbuvir
Ledipasvir
Simeprevir
Velpatasvir/sofosbuvir

--------------------------------CONTRAINDICATIONS-----------------------------­ EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 872,45 KB

Share Document on Facebook

Similar Documents

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

Microsoft WordDOCX

Microsoft WordDOCX

DocID: 1rnqZ - View Document

Beilage 1: Arzneimittelmonographien

Beilage 1: Arzneimittelmonographien

DocID: 1rinj - View Document

SAFETY DATA SHEET Page 1 of Total 6 Date of Issue: August 2016 SDS No. FMC/RAD/1  SECTION 1

SAFETY DATA SHEET Page 1 of Total 6 Date of Issue: August 2016 SDS No. FMC/RAD/1 SECTION 1

DocID: 1rdYu - View Document

imatinib and colon cancer. imatinib availability imatinib and cml imatinib and tight junction cancer imatinib prostate dercum and imatinib zactima plus imatinib

imatinib and colon cancer. imatinib availability imatinib and cml imatinib and tight junction cancer imatinib prostate dercum and imatinib zactima plus imatinib

DocID: 1rdbp - View Document